ArticlePain management2025
Millimeter wave neuromodulation for the management of osteoarthritis pain: a real word evidence study.
Article in Pain management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionManaging osteoarthritis aims to relieve pain, improve joint function and quality of life. Current guidelines recommend combining non-drug and pharmacological approaches. A non-medication solution integrating an endorphin-stimulating millimeter wave device, mobile application, and coaching program was evaluated.
methodsThis combined approach is evaluated in a real-world evidence study over three months in patients with osteoarthritis-related pain. The primary endpoint was patient-perceived change at three months using the Patient Global Impression of Change (PGIC). Secondary outcomes, assessed at baseline and three months, included pain intensity (mean and maximum), frequency of pain crises, quality of life, sleep, mental health, and medication use.
resultsAmong 156 participants completing follow-up, 80.1% reported improvement (PGIC > 4). Quality of life improved by 29.8%, while sleep and mental health improved by 13.1% and 13.5%, respectively. Mean and maximum pain intensity decreased by 33.9% and 33.1%. Pain crises became less frequent, and patients reported reduced medication use.
conclusionThese results align with recent randomized controlled trial findings, supporting millimeter wave neuromodulation as an innovative, non-drug strategy targeting both nociceptive and nociplastic pain mechanisms to improve quality of life in osteoarthritis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.